UnknownPhase 4

Effects of Carvedilol on Suppressing the Premature Ventricular Complex/Ventricular Tachycardia From Outflow Tract

South Korea104 participantsStarted 2017-09-05

Plain-language summary

Carvedilol is known to be effective in reducing ventricular arrhythmias and mortality in patients with heart failure. It is suggested that one of the mechanisms is its ability to block store overload-induced Calcium release which activates spontaneous calcium release by Ryanodine receptors. Ventricular outflow tract tachyarrhythmia is known to be associated with calcium overload due to activation of Ryanodine receptors. The aim of this study is to evaluate the efficacy of Carvedilol on premature ventricular complex(PVC)/ventricular tachycardia(VT) originating from outflow tract.

Who can participate

Age range19 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with ventricular premature complexes/ventricular tachycardias originating from ventricular outflow tract confirmed on the 12-lead surface ECG * Patients with PVC burden of 5% or more in 24-hour Holter monitoring * Patients with normal left ventricular function * left ventricular ejection fraction ≥50% * Patients without structural heart disease Exclusion Criteria: * Pregnant, trying to become pregnant or breast feeding * History of bronchial asthma * History of coronary arterial disease

What they're measuring

PVC burden

Timeframe: 3 months after reaching the maximum tolerated dose

Trial details

NCT IDNCT03587558

SponsorKeimyung University Dongsan Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-12-31

Contact for this trial

Jongmin Hwang, M.D., Ph.D.

+82-53-250-7333 dsmcep@dsmc.or.kr

View on ClinicalTrials.gov More Ventricular Premature Complexes trials